Экстрамедуллярные рецидивы после трансплантации аллогенных гемопоэтических клеток и трансфузий лимфоцитов донора
Larisa A. Kuzmina, Л С Любимова, Larisa Pavlovna Mendeleeva et al. · Клиническая онкогематология. Фундаментальные исследования и клиническая практика · 2011
SUMMARY The aim of the study was to investigate the frequency and the time of extramedullary relapses development after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and donor lymphocyte infusion (DLI) and to find the optimal treatment. 48 patients (35 — acute leukemia, 8 — chronic leukemia, 5 — myelodysplastic syndrome) after allo-HSCT performed during 2007–2010 were included. The median age was 32 (19–63) years, male / female — 24/24. In 44 cases donors were HLA-identical siblings, in 3 cases — syngeneic, in 1 case donor was 2 HLA-antigen incompatible. Conditioning regimen was myeloablative in 36 cases, nonmyeloablative in 14 cases. Median follow-up was 27 (8–45) months. 35 of 48 patients (72,9 %) are alive for the moment. The mortality was 27,1 % (13 patients). The main mortality cause was relapse, diagnosed only in patients with acute myeloid leukemia (AML) (in 48 % of patients with AML). It is important to note, that most patients with relapses received allo-HSCT in resistant / relapsed leukemia or in II remission. Extramedullary relapses, including isolated CNS relapses, were diagnosed in 15 % patients. More than a half of these relapses developed during or after bone marrow relapse. Median time between allo-HSCT and diagnosis of extramedullary relapse was 8 months. No signs of the disease were registered after isolated CNS relapses. In patients with granulocytic sarcoma effects were achieved only after chemotherapy with or without radiotherapy.
Cited by 0 works.
Authors
- Larisa A. Kuzmina
- Larisa Pavlovna Mendeleeva
- Evgenia I. Zhelnova
- Н. А. Петинати
- Rashit Bogdanov
- В А Васильева
- Т. В. Гапонова
- Ирина Костина
References
- Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse [see comments]
- Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation.
- Low‐dose azacitidine after allogeneic stem cell transplantation for acute leukemia
- The risks of central nervous system relapse and leukoencephalopathy in patients receiving marrow transplants for acute leukemia
- Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy
- Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course
- Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome
- Specific skin manifestations in CD56 positive acute myeloid leukemia
- Role of leukemia cell invadosome in extramedullary infiltration
- Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia.